Academic and commercial partnerships
Because of its unique research, Abliva has established good relationships with the academic and business community across the world, in Europe, Asia and the US, which has created great potential for successful partnerships.
Abliva collaborates with the Korean pharmaceutical company Yungjin Pharm around the clinical development of the KL1333 project for the treatment of primary mitochondrial disorders.
Isomerase of the UK is one of Abliva’s key partners. This collaboration focuses primarily on development of Abliva’s chemistry platforms within Abliva’s projects for treating primary mitochondrial disorders. The collaboration between the two companies’ researchers is also a creative hotbed for identifying new development platforms in the same area, and with its drug development expertise, Isomerase offers valuable backing for Abliva’s projects.
Through the NeuroVive Asia Ltd. subsidiary in Hong Kong, Abliva has partnerships with the Chinese pharmaceutical company Sihuan Pharmaceutical, and with Sanofi in South Korea. Abliva also partners with a range of Contract Research Organizations (CROs).
Abliva has also entered into a commercial partnership with Oroboros Instruments in Austria.
In addition to these partners, Abliva collaborates with a range of academic institutions all over the world, including CHOP (Children’s Hospital of Philadelphia), Newcastle University and University College London (UCL) in the UK.
MD, Internist and Medical Geneticist, Director of Mitochondrial Disease Program at Massachusetts General Hospital, Associate Professor at Harvard Medical School, US. President of the Mitochondrial Medicine society.
MD, Paediatric Neurologist, Director of Neuro-Developmental Science Center, Akron Children’s Hospital. Professor of pediatrics and integrative medical sciences at Northeast Ohio Medical University, US.